PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Allergic rhinitis (Beclometasone dipropionate - Allergic rhinitis)

Records returned : 30 (on 20 Apr 2025 at 00:35:01). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
12.02.01
Beclometasone dipropionate
Allergic rhinitis
Green (see narrative)
Formulations :
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Beconase Aqueous 200 dose container is the most cost effective nasal steroid spray for primary care. NOTE Beconase Hayfever and other container sizes (180 dose and 100 dose) are much more expensive and should not be used.
03.01.02
12.02.01
Ipratropium bromide
Allergic rhinitis
Green
Formulations :
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
03.04.01
Cetirizine hydrochloride
Allergic rhinitis
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Prescribe generically. Available to buy over the counter.
03.04.01
Loratadine
Allergic rhinitis
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Prescribe generically. Available to buy over the counter.
03.04.01
Allergic rhinitis
Green
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Loratadine 5mg/5ml oral solution sugar free is the preferred option in patients unable to swallow tablets.Available to buy over the counter.
03.04.01
Chlorphenamine maleate
Allergic rhinitis
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
11.04.02
12.02.01
Azelastine hydrochloride
Allergic rhinitis
Green
Formulations :
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
03.04.01
Fexofenadine hydrochloride
Allergic rhinitis
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
2nd line to loratadine / cetirizine tablets. 120mg tablets available to buy over the counter.180mg tablets NOT licensed for allergic rhinitis. 30mg reserved for paediatrics.
03.04.01
Cetirizine hydrochloride
Allergic rhinitis
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Loratadine 5mg/5ml sugar free oral solution (from 2 years) is the 1st-line option. Cetirizine liquid is considerably more expensive and is a 2nd line option for patients unable to swallow tablets.
03.04.01
Desloratadine
Allergic rhinitis
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Not a 1st-line option. Use cetirizine or loratadine 1st line.
03.04.01
Levocetirizine
Allergic rhinitis
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Not a 1st-line option. Use cetirizine or loratadine 1st-line.
06.03.02
10.01.02
11.04.01
12.02.01
Triamcinolone acetonide
Allergic rhinitis
Green (see narrative)
Formulations :
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Beclometasone (200 dose container) is the preferred intranasal steroid for allergic rhinitis. Triamcinolone is considered to be a 3rd / 4th line agent.
12.02.01
Fluticasone furoate
Allergic rhinitis
Green (see narrative)
Formulations :
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Beclometasone is the preferred intranasal steroid for allergic rhinitis. If fluticasone is required, prescribe as fluticasone furoate in Primary Care (less costly option). Prices may vary in secondary care. NOTE: ASPH restrict fluticasone furoate to use in paediatrics due to smaller nozzle size.
12.02.01
Fluticasone propionate (Nasal)
Allergic rhinitis
Green (see narrative)
Formulations :
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Beclometasone is the preferred intranasal steroid for allergic rhinitis. If fluticasone is required, prescribe as fluticasone furoate in Primary Care (less costly option). Prices may vary in secondary care. NOTE: ASPH recommend fluticasone furoate in paediatrics due to smaller nozzle size.
Fluticasone with azelastine
Allergic rhinitis
Green (see narrative)
Formulations :
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Reserved for use where monotherapy is inadequate. Not 1st line.
12.02.01
Mometasone furoate
Allergic rhinitis
Green (see narrative)
Formulations :
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Beclometasone (200 dose container) is the preferred intranasal steroid for allergic rhinitis. Mometasone is 2nd line, once daily.
12.02.01
Mometasone furoate with olopatadine
Allergic rhinitis
Green (see narrative)
Formulations :
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Reserved for use where monotherapy is inadequate. Not 1st line.
01.05.02
03.02.00
05.03.06
06.03.02
12.02.01
Budesonide
Allergic rhinitis
Green (see narrative)
Formulations :
  • Nasal spray
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Beclometasone (200 dose container) is the preferred intranasal steroid for allergic rhinitis. Budesonide is 2nd line, once daily option.
06.03.02
10.01.02
11.04.01
12.02.01
Triamcinolone acetonide
Allergic rhinitis
Non Formulary
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
03.04.01
Levocetirizine
Allergic rhinitis
Non Formulary
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Loratadine liquid is 1st line in patients unable to swallow tablets (from 2 years of age).
03.04.01
Desloratadine
Allergic rhinitis
Non Formulary
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Loratadine liquid is 1st line in patients unable to swallow tablets (from 2 years of age)
03.04.01
Cetirizine hydrochloride
Allergic rhinitis
Non Formulary
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
03.04.01
Acrivastine
Allergic rhinitis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
03.04.01
Bilastine
Allergic rhinitis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
03.04.01
11.04.02
Ketotifen fumarate
Allergic rhinitis
Non Formulary
Formulations :
  • Capsules
  • Elixir
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
03.04.01
04.06.00
Promethazine hydrochloride
Allergic rhinitis
Non Formulary
Formulations :
  • Oral solution
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
03.04.01
Mizolastine
Allergic rhinitis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Important
Discontinued April 2024. Refer to guidelines for alternatives.
03.04.01
Rupatadine fumarate
Allergic rhinitis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
03.04.02
White Birch pollen allergen extract
Allergic rhinitis
See narrative
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD2
03.04.02
House dust mites allergen extract
Allergic rhinitis
See narrative
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD2
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More